What is Titan Pharmaceuticals Book Value per Share?
Titan Pharmaceuticals's book value per share for the quarter that ended in Mar. 2024 was $6.66.
During the past 3 years, the average Book Value Per Share Growth Rate was -4.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -50.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -51.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Titan Pharmaceuticals was 133.20% per year. The lowest was -132.50% per year. And the median was -35.40% per year.
During the past 13 years, the highest P/B Ratio of Titan Pharmaceuticals was 80.79. The lowest was 0.51. And the median was 6.56.
Titan Pharmaceuticals Book Value per Share Historical Data
The historical data trend for Titan Pharmaceuticals's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Titan Pharmaceuticals's Book Value per Share
For the Biotechnology subindustry, Titan Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Titan Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Titan Pharmaceuticals's PB Ratio falls into.
Titan Pharmaceuticals Book Value per Share Calculation
Titan Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Titan Pharmaceuticals (NAS:TTNP) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Titan Pharmaceuticals Book Value per Share Related Terms
Thank you for viewing the detailed overview of Titan Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Titan Pharmaceuticals (Titan Pharmaceuticals) Business Description
Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TTNP has been successfully added to your 